Home » World Microbe Forum: Industry & Science Symposium
World Microbe Forum: Industry & Science Symposium
Culture Independent Rapid Diagnostics Impact on Sepsis Management
Speakers: Dr. James Snyder, Chief of Microbiology, University of Louisville Hospital, Louisville, KY, and Dr. Todd McCarty, ID Fellowship Program Director, University of Alabama School of Medicine, Birmingham, AL.
Non-culture-based tests (NCTs) provide faster and more accurate results than the current standard of care that relies upon culture-based testing. T2 Biosystems Panels provide results directly from a whole blood sample, often before the second dose of antibiotics is delivered. In this presentation, Dr. James Snyder discusses best practices for the implementation of T2Candida® and T2Bacteria® Panels from first-hand experience at the University of Louisville Hospital. Viewers will also gain insight on the utilization of T2Candida and its impact on clinical outcomes from Dr. Todd McCarty’s experience at the University of Alabama at Birmingham School of Medicine.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.